How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Population Screening Market
- By Screening Type: Genetic Screening, Biochemical Screening, Imaging Screening, Immunological Screening, Molecular Screening
- By Application: Cancer Screening, Infectious Disease Screening, Cardiovascular Disease Screening, Metabolic Disorder Screening, Prenatal Screening
- By End User: Hospitals, Diagnostic Laboratories, Clinics, Government Health Agencies, Research Institutes
- By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Magnetic Resonance Imaging (MRI), Ultrasound Screening
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Genetic Screening leads By Screening Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Population Screening Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Screening Type 5
Application 5
End User 5
Technology 5
Companies profiled
Roche Diagnostics
Abbott Laboratories
Thermo Fisher Scientific
Siemens Healthineers
Becton Dickinson and Company (BD)
Illumina Inc.
Bio-Rad Laboratories
PerkinElmer Inc.
Hologic Inc.
Qiagen N.V.
F. Hoffmann-La Roche AG
Agilent Technologies
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →PerkinElmer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Qiagen N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Agilent Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Myriad Genetics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Guardant Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Natera
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,131M by 2033 · 10.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Genetic Screening57.5
- Biochemical Screening11.0
- Imaging Screening7.5
- Immunological Screening9.8
- Molecular Screening14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$933.3M → $2,061M · 10.4%
Europe$650.5M → $1,390M · 10.0%
Asia Pacific$593.9M → $1,287M · 10.1%
Latin America$367.7M → $880.9M · 11.5%
Middle East and Africa$282.8M → $623.0M · 10.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.112026
10.132027
10.132028
10.152029
10.162030
10.172031
10.192032
10.192033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche Diagnostics17.7
- Abbott Laboratories11.5
- Thermo Fisher Scientific10.9
- Siemens Healthineers14.5
- Becton Dickinson and Company (BD)7.9
- Illumina Inc.9.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Screening Type35.5%
Application10.8%
End User23.5%
Technology30.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe22.3
- Asia Pacific20.6
- Latin America14.1
- Middle East and Africa10.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche Diagnostics | 85 | 92 | 90 | 97 | 74 | 85 | 87 |
| Abbott Laboratories | 75 | 79 | 90 | 92 | 73 | 73 | 80 |
| Thermo Fisher Scientific | 75 | 71 | 78 | 80 | 83 | 86 | 79 |
| Siemens Healthineers | 63 | 62 | 63 | 72 | 73 | 77 | 68 |
| Becton Dickinson and Company (BD) | 76 | 52 | 60 | 63 | 71 | 68 | 65 |
| Illumina Inc. | 68 | 70 | 51 | 60 | 56 | 65 | 62 |
| Bio-Rad Laboratories | 58 | 66 | 41 | 45 | 48 | 48 | 51 |
| PerkinElmer Inc. | 50 | 50 | 57 | 59 | 36 | 42 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche Diagnostics
- Abbott Laboratories
- Thermo Fisher Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche Diagnostics | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Abbott Laboratories | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Thermo Fisher Scientific | ◐ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Siemens Healthineers | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| Becton Dickinson and Company (BD) | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| Illumina Inc. | ◐ | ◐ | ◐ | − | − | ◐ |
| Bio-Rad Laboratories | ◐ | − | − | − | − | ◐ |
| PerkinElmer Inc. | − | − | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche Diagnostics87
2Abbott Laboratories80
3Thermo Fisher Scientific79
4Siemens Healthineers68
5Becton Dickinson and Company (BD)65
6Illumina Inc.62
7Bio-Rad Laboratories51
8PerkinElmer Inc.49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Roche DiagnosticsAbbott LaboratoriesThermo Fisher Scientific
Challenger1
Strong scale, closing on the leaders.
Siemens Healthineers
Contender2
Focused players with pockets of strength.
Becton Dickinson and Company (BD)Illumina Inc.
Niche2
Specialists in a single segment or region.
Bio-Rad LaboratoriesPerkinElmer Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Screening Type in North America, then scale across Population Screening Market — a $395M beachhead inside a $7.47B market.
Beachhead (SOM)$395Mobtainable near-term
Serviceable (SAM)$2.60Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Genetic Screening
Best fit — highest urgency & budget in Screening Type.
Economic buyer81 fit
Biochemical Screening
Strong fit — clear ROI and a fast path to value.
End user68 fit
Imaging Screening
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Screening Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Screening Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Population Screening Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation14%
Closed-won7%
$12.7KCAC
$47KLTV
3.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Population Screening Market is a durable-growth opportunity — $3.47B by 2033, compounding at 9.8%.
TAM · 2025$1.65Btoday
TAM · 2033$3.47Bforecast
CAGR9.8%2027–2033
Cumulative$22.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.47BTotal addressable market
SAM$1.30BServiceable available market
SOM$285MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.8% CAGR
Demand compounds through 2033, outpacing GDP across Screening Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Screening Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.47BLarge & growingTAM by 2033 at 9.8% CAGR
$1.30BServiceable nowreachable with today’s model
$285MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.71BBear6.4% CAGR
$3.47BBase9.8% CAGR
$4.45BBull12.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Population Screening Market — a $2.51B market by 2033. Plan: grow share from 7.0% to 12.5%.
Market size · 2033$2.51Btotal addressable
Market CAGR8.0%2027–2033
Target share12.5%from 7.0% today
Revenue ambition$314Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 12.5% | At risk |
| Revenue | $192M | $314M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 30.9% | 42.2% | On track |
| Customer retention | 86.9% | 96.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Screening Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Screening Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $35M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Screening Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Population Screening Market conversation — a $1.42B market you can size, segment and defend in minutes.
Market size · 2033$1.42Btotal opportunity
Growth11.2%CAGR to 2033
Addressable buyers980+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Screening Type
Goal Grow share in Screening Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 4 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Roche DiagnosticsAbbott LaboratoriesThermo Fisher ScientificSiemens HealthineersBecton Dickinson and Company (BD)Illumina Inc.Bio-Rad LaboratoriesPerkinElmer Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Population Screening Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Population Screening Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Population Based Health Services Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportPool Test Kit Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportPonatinib HCl Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportPomalidomide API Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportPolyvinyl Chloride Syringe Trays Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPolyvinyl Alcohol in Medical Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportPolyvinyl Alcohol Eye Drops Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportPolyvinyl Alcohol Eye Drop Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportPolyvalent Streptococcus Pneumoniae Active Immunizing Agent Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportPolyvalent Streptococcus Pneumococcal Vaccines Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportPolyvalent Antivenom Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPolyurethane Wound Care Product Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.